Genmab — Januar 2018
-
De første preliminære data i solide tumorer vil nok være svære at fortolke, da de næppe vil være klare - her må vi nok forlade os på handling fremfor ord - altså gør diverse ejere af Checkpoint inhibitorer mere ved sagen hurtigt eller syner det hen i snik snak
-
-
-
Genmab-partner leverer bedre regnskab end ventet (Novartis): http://borsen.dk/nyheder/virksomheder/artikel/1/357425/genmab-partner_leverer_bedre_regnskab_end_ventet.html?utm_source=forside&utm_campaign=nyhed_09
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

